ESR1 and breast carcinoma: RBCK1 can regulate ERalpha-positive breast cancer cell cycle progression and proliferation by supporting transcription of ERalpha and cyclin B1 (45), and could be a predictive marker of response to endocrine therapy in breast cancer (46).